2Nd-Line Therapies after 1St-Line Therapy with Folfiri in Combination with Cetuximab or Bevacizumab in Patients with Kras Wild-Type Metastatic Colorectal Cancer (Mcrc)-Analysis of the Aio Krk 0306 (fire 3)- Trial

D. Modest,S. Stintzing,L. Fischer von Weikersthal,T. Decker,A. Kiani,U. Vehling-Kaiser, S.E. Al Batran,T. Heintges,C. Lerchenmüller,C. Kahl,G. Seipelt,F. Kullmann,M. Stauch,W. Scheithauer,S. Held,C. Giessen,A. Jung, R. Kirchner,V. Heinemann

Annals of oncology（2014）

引用 2|浏览23

暂无评分

摘要

Aim: To investigated choice and duration of 2nd-line therapies according to 1st-line efficacy as well as overall survival (OS) according to 2nd-line therapy in FIRE-3: FOLFIRI plus either cetuximab (arm a) or bevacizumab (arm b) as 1st-line treatment of KRAS exon 2 wild-type mCRC.

查看译文

关键词

Metastatic Colorectal Cancer

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要